Okay. Thanks very much.
Dr. Bechard, thank you very much for being here.
Obviously, on the heels of Dr. Hoskins' report, tackling national pharmacare has to be a priority. I think there are some jurisdictional things that need to be sorted out and that I hope won't get in the way. You did an excellent job, I thought, of summarizing the fact that this can actually pass on a cost savings to the taxpayer and also increase social good. I'm curious as to whether you've identified a certain sector of society that will be the primary beneficiary of taking on this kind of approach.